The Phase III POTENT trial (jRCTs051180057/CRB5180002) investigated the efficacy of S-1 with adjuvant endocrine therapy in patients with stage I to IIIB ER-positive, HER2-negative early breast cancer [15]. The gene discussed is ERBB2; the disease is breast cancer.